63676-22-2
63676-22-2
Chemical Structure
Estrogen receptor modulator 1
- CAS No.: 63676-22-2
- Formula:C14H10O2S
- Molecular Weight:242.29
IUPAC Name: 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
InChIKey: MDGWZLQPNOETLH-UHFFFAOYSA-N
SMILES: OC1=CC=C(C=C(C2=CC=C(O)C=C2)S3)C3=C1
Biological Activity: Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Estrogen receptor modulator 1 | 99.91% | Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.69
HY-129156HS-1793 -
Similarity Score 0.69
HY-137005CS1 -
Similarity Score 0.67
HY-128145HSD17B13-IN-41 -
Similarity Score 0.65
![[1,1′:4′,1′′-Terphenyl]-3,4′′,5-triol Chemical Structure](//file.medchemexpress.com/product_pic/hy-120654.gif)
HY-120654[1,1′:4′,1′′-Terphenyl]-3,4′′,5-triol -
Similarity Score 0.64
HY-157665HSD17B13-IN-39 -
Similarity Score 0.63
HY-N13568Flavanthrinin -
Similarity Score 0.61
HY-19468ERB-196 -
Similarity Score 0.61
HY-N5035Moscatin -
Similarity Score 0.61
HY-132863FTO-IN-2 -
Explore the MedChemAI to find more analogs
![[1,1′:4′,1′′-Terphenyl]-3,4′′,5-triol Chemical Structure](http://file.medchemexpress.com/product_pic/hy-120654.gif)
References
- [1]. Brogi S, et al. 3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors. Eur J Med Chem. 2013 Sep;67:344-51. [Content Brief]
- [2]. Molloy ME, et al. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. Mol Cancer Ther. 2014 Nov;13(11):2515-26. [Content Brief]
